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Protection from progressive renal failure and hyperparathyroid bone
remodeling by WR-2721. In chronic renal failure (CRF), secondary
hyperparathyroidism (sHPT) plays a major role in skeletal lesions and
also probably in the deterioration of renal functions consecutive to
nephrocalcinosis. In this study we tested whether WR-2721 S-,2-(3-
aminopropylamino)-ethylphosphorothioic acid), an inhibitor of parathy-
roid hormone (PTH) secretion, could prevent the deleterious effects of
5HPT at both the bone and kidney level in an animal model of CRF.
Rats were either sublotally nephrectomized (NX) or sham-operated
(SHAM). They were then pairfed a high phosphorus (1.4%), middle Ca
(0.6%) diet. This regimen accelerated the deterioration of renal function
in NX rats which displayed signs of severe sHPT in bone (three- to
fourfold increase in osteoclast number and resorption surfaces) and
kidney (sixfold increase in Ca content) after four weeks. Chronic
administration of WR-2721 (20 mg = 0.093 mmol/kg s.c. twice daily)
during four weeks completely prevented the progressive elevation of
both plasma urea and inorganic phosphate, and the fall of plasma Ca. It
also prevented kidney Ca accumulation to the same extent as parathy-
roidectomy. However, WR-272l given at this dose only partially
prevented the histomorphometric indices of increased bone resorption
and formation. This discrepant response suggests that WR-2721 could
exert an additional protective effect at the kidney level that might be
related to its property of acting as a free radical scavenger. In
conclusion, this study suggests that WR-2721 might be a useful com-
pound in CRF, not only because it inhibits PTH secretion, but also
because it could protect against the deleterious effect of secondary
hyperparathyroidism on kidney functions.
Parathyroid hormone (PTH) plays a major role in the skeletal
lesions that develop during the course of chronic renal failure
(CRF) [1—3]. PTH is certainly responsible for the increase in
bone remodeling that represents a salient feature of renal
osteitis fibrosa cystica [1, 2]. Furthermore, secondary hyper-
parathyroidism in uremia is probably implicated in the in-
creased calcium [Cal content observed in some soft tissues,
particularly in the renal parenchyma [4—7]. Thus, by favoring
the development of nephrocalcinosis [8, 91 in uremia, PTH can
be considered as a nephrotoxic agent that would accelerate the
deterioration of the remaining functional nephrons. More re-
cently, it has been suggested that an increase in circulating PTH
might also exert deleterious effects on the hematopoietic,
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nervous and cardiovascular systems, and thereby contribute to
the pathogenesis of several other uremic manifestations [10—
12]. The precise mechanism leading to hyperparathyroidism in
CRF has not yet been clearly elucidated, since other factors
than hypocalcemia and low plasma level of I ,25-dihydroxyvi-
tamin D1 appear to be implicated [13]. Therefore, it seems
important to continue exploring the possibility of controlling
PTH secretion by other means than the maintenance of high
plasma levels of Ca and I ,25-dihydroxyvitamin D, since this
approach may aggravate the trend for soft tissue Ca deposition
in CRF. In this context, it appeared worth considering a
recently discovered powerful inhibitor of PTH secretion, the
organic phosphorothioate WR-272 1 [S-,2-(3-aminopropylamino)-
ethylphosphorothioic acid]. Previous studies in patients and
animals demonstrated that WR-2721 can inhibit PTH secretion
in eu- and hyperparathyroidism [14—181. Furthermore very
recently it has been shown that WR-2721 can prevent PTH-
dependent nephrocalcinosis in rats with intact renal mass [191.
In the present study we tested the efficacy of WR-2721 in an
animal model of progressive CRF with marked expression of
hyperparathyroidism at the bone and kidney levels.
Methods
Animal prepara (jo/i
Chronic renal failure (CRF) was induced in male Wistar rats
of 250 to 300 g body weight by a two-stage procedure similar to
that described in a previous report [20]. The first operation
involved superficial cauterization of one kidney, leading to
about a 30% reduction in the renal mass. The second operation
consisted of the removal of the controlateral kidney one week
later. Both surgical procedures were done under pentobarbital
anesthesia.
Simultaneously, control animals were sham-operated (SHAM).
Then, all subtotally nephrectomized (NX) and SHAM animals
were pairfed a semi-synthetic diet (KIlba, Klingenthalmuehle
AG, Switzerland) containing 1.4 g/l00 g phosphorus and 0.6
g/lOO g Ca. This food, being deficient in vitamin D, had 10 IU
cholecalciferol dissolved in vegetable oil added to the daily
ration. Preliminary studies indicated that in NX but not in
SHAM animals the selected diet induced the expression of
severe hyperparathyroidism at the bone and kidney levels, and
accelerated the deterioration of kidney functions in agreement
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Table 1. Effect of chronic administration of WR-2721 on plasma biochemical variables in sham-operated (SHAM) and subtotally
nephrectomized (NX) rats
Urea Ca Pi
SHAM untreated 4 74.6 2.3 5,43 0.21 2.27 0.04 2.20 0.16
SHAM WR-272l 5 72.1 0.8 5.93 0.25 2.28 0.01 2.46 0.36
NX untreated 4 77.7 3.8 21.46 2.96a 1.59 0.12 7.41 0.73"
NX + WR-2721 4 71.1 0.4 8.89 0,68d 2.32 0.03 2.66 0.07'
All values are mean SEM. N = number of rats. WR-272l was administered at the daily dose of 20 mg/kg body wt s.c. during 4 weeks before
the plasma biochemical determinations. During this period, the mean food consumption (g/day) was: SHAM untreated, 19.3 0; SHAM + WR-
2721, 19.3 0; NX untreated, 18.9 0.4; NX + WR-272l: 17.9 0.9.
a p < 0 .01; I) p < 0.001 for difference between NX untreated and NX + WR-272l treated rats. c p < 0.05; d p < 0.001 for difference between
NX + WR-2721 treated and SHAM untreated rats
with similar experimental models of CRF in the rat [21, 221. In
one experiment, a group of rats was parathyroidectomized
(PTX) seven days before reducing the renal mass. Only animals
displaying a plasma Ca equal or below 1.88 ma (7.5 mg/l00 ml)
48 hours after the parathyroidectomy were considered as PTX
and were kept in the study.
Subcutanous injections of WR-2721 (20 mg = 0.093 mmol/kg
twice daily) or its solvent were started on the same day as the
semi-synthetic diet. WR-272l was from the Drug Synthesis and
Chemistry Branch, Division of Cancer Treatment, National
Cancer Institute (Bethesda, Maryland, USA). The drug was
dissolved in HEPES solution with the pH adjusted to 7.4 by
Tris buffer just before the injection. Each experiment lasted
four weeks starting on the first day of the introduction of the
high Pi diet.
In the first study, four groups of animals were investigated: I)
SHAM, untreated; 2) SHAM, WR-2721 treated; 3) NX, untreat-
ed; 4) NX, WR-2721 treated. The administration of WR-272l or
its solvent was started the same day as the high Pi diet. At the
end of the experiment, blood samples were taken from a tail
vein. Afterwards, the animals were anesthetized with ether and
exsanguinated by aortic puncture. The tibia were dissected out
for later histomorphometric examination.
The second study consisted of the following groups: 1)
SHAM, untreated; 2) NX, untreated; 3) NX, WR-272l treated;
4) PTX, NX. The treatment with WR-2721 was initiated at the
same time as in the first study. The plasma concentrations of
urea, Ca and Pi were monitored once a week throughout the
treatment period. At the end of this experiment, glomerular
filtration rate (GFR) was determined by inulin clearance as
previously described [15, 20]. Animals were put into restrictive
cages after having received their last injection of WR-2721.
Then a catheter was inserted into a tail vein to administer a
continuous intravenous infusion of isotonic NaCl solution con-
taining 1 jsCi/ml of methoxy-3H inulin at a rate of 2.5 mI/hr
during 180 minutes. After an equilibration period of 30 minutes,
urine was collected during the remaining 150 minutes. At the
end, one blood sample was taken from a hindlimb vein. Then.
the animals were sacrificed by exsanguination under ether
anesthesia. The blood sample was collected by aortic puncture
in heparinized syringues about four hours after the last injection
of WR-272l and was used for the determination of plasma
immunoassayable parathyroid hormone (iPTH). After the ex-
sanguination, the remaining kidneys were excised, deep-frozen
and lyophilized in order to determine their Ca content later.
The third study consisted of only three groups I) SHAM,
untreated; 2) NX, untreated; 3) NX, WR-272l treated. The
WR-2721 treatment was introduced only two weeks after start-
ing the high Pi diet in order to examine whether the drug could
stop or reverse the deterioration of renal function. Blood
samples were taken just before and two weeks after initiating
the WR-272l treatment.
The time interval between the removal of the controlateral
(second operation) and the introduction of the high inorganic
phosphate (Pi) diet was one day for the first and third studies,
and five days for the second study.
Analytic methods
Plasma and urine variables. Plasma Ca was determined by
atomic absorption spectrophotometry. Total plasma proteins,
Pi and urea nitrogen were measured by colometric methods as
previously described [15, 20]. Activity of 3H-inulin was deter-
mined by scintillation counting. The lyophilized kidneys were
incinerated, the ash residues dissolved in 1 N HCI and Ca
determined as described above. Plasma PTH was determined
with an N-terminal specific radioimmunoassay (Nichols Insti-
tute Diagnostics, San Juan Capistrano, California, USA). This
RIA has been previously validated for the determination of
circulating PTH in the rat [231.
Bone variables. The whole tibia was fixed and dehydrated
without prior decalcification in increasing concentrations of
ethanol, and then embedded in methylmethacrylate. Frontal 8
m thick sections of the head of the tibia were cut with a Jung
K microtome. Measurements of osteoid parameters were per-
formed on four sections stained by Solochrome CyaninR and the
resorption parameters on four sections stained by Goldner's
method. Bone surfaces were measured with a semiautomatic
image analyzer (Videoplan) and the osteoid volume was mea-
sured with a manual method at a magnification of 320. The
histological evaluation was performed in cancellous bone from
the epiphysis of proximal tibia, above the growth plate. The
following parameters were measured:
—The total resorption surfaces (RS) which are the percent-
age of trabecular surfaces showing Howship's lacunae with
or without osteoclast.
—The number of osteoclasts (OC) per square millimeter of
trabecular bone section.
N
Total protein
g/!irer ,nmol/liter
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Table 2. Effect of chronic administration of WR-2721 on histomorphometric variables in sham-operated (SHAM) and subtotally
nephrectomized (NX) rats
SHAM
untreated
SHAM +
WR-2721
NX
Resorption surfaces
N 0%
—The relative osteoid surfaces (OS) which are the percent-
age of the trabecular surfaces covered with osteoid.
—The relative osteoid volume (OV) which represents the
percentage of trabecular bone tissue occupied by osteoid.
—The thickness index of osteoid seams (TIOS), which
validly estimates the true thickness of osteoid seams in
metabolic bone disease [24], was calculated as the ratio
(OV/OS) X 100.
Statistical analysis
All results are expressed as means standard error of means
(sEM) unless otherwise indicated. The significance of differ-
ences was evaluated by a two-sided, unpaired or paired Stu-
dent's I-test.
Results
First study
The repercussion of the selected CRF model on plasma
chemistry is presented in Table 1. Four weeks after the reduc-
tion of renal mass and initiation of the high Pi diet, plasma urea
was about fourfold higher in untreated NX rats as compared to
pair-fed SHAM counterparts. This was associated with marked
hypocalcemia and hyperphosphatemia. In WR-272 1-treated NX
rats plasma urea was still significantly higher than in SHAM
animals. However, it was strikingly lower than in untreated NX
rats. This effect was associated with a virtual normalization of
both hypocalcemia and hyperphosphatemia. Note that the
chronic administration of WR-272l did not influence signifi-
cantly the plasma levels of urea, Ca and Pi in SHAM animals.
The bone histomorphometric analysis of these four groups of
animals is presented in Table 2. It shows that, in this animal
model of CRF, a marked increase of bone remodeling was
present. Indeed, in untreated NX rats both the bone resorption
(RS and OC) and the bone formation variables (OV and OS)
were increased as compared to SHAM animals. The thickness
index of osteoid seams, however, were unchanged in NX
animals. These histomorphometric findings are characteristic of
pure hyperparathyroidism 125]. They do not suggest the con-
comitant presence of osteomalacic bone lesions. The WR-2721-
treated NX rats showed a significantly smaller increase in bone
resorption and bone formation indices than the untreated NX
rats. However, these variables remained higher than in SHAM
animals. No significant difference in the histological indices was
noted between untreated and WR-272 I-treated SHAM animals.
Osteoid
volume (OV)
Osteoid
surface (OS)Osteoclast Thickness index
number of osteoid seams
per mm2 (0 V/OS) X 100
4 10.4 0.1 2.0 + 0.2 1.1 + 0.4 8.9 3.5 15.9 3.3
5 15.3 -- 2.2 2.7 0.5 0.9 0.3 6.6 1.3 13.2 -- 1.9
untreated 4 36.7 l.4 7.4 0.6' 5.2 Øb 33.2 l.8 15.6 1.5
NX +
WR-2721 4 28.1 2•0d 5.1 0•4d 2.6 0.3c 20.5 4.lc 12.7 0.4
All values are mean SUM. N = number of rats. WR-2721 was administered at the daily dose of 20 mg/kg body wt s.c. during 4 weeks.
P < 0.05; b p < 0.01 for difference between NX untreated and NX + WR-2721 treated rats. P < 0.05; d p < 0.001 for difference between
NX + WR-2721 treated and SHAM untreated rats.
No significant statistical difference was found between values from SHAM untreated and SHAM WR-2721 treated rats.
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Fig. 1. Effect cf chronic administration qt WR-272 / as compared to
prior parathyroidectotny on the evolution of plasma urea in subtota//y
nephreciomnized rats (NXfed a high Pj diet since day 0. Each symbol
is the mean SUM of 5 to 6 rats. ***p < 0.001 for difference between
NX untreated (S----•) and either NX + WR-272I treated (•—•) or
NX-PTX (• . . . . •) rats. P < 0.05, ttP < 0.01, tttP < 0.001 for
difference between either NX + WR-2721 or NX-PTX and SHAM
(A—L\).
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Second study
This study similar to the first one was undertaken: a) to
monitor the course of renal deterioration; b) to determine
precisely GFR after four weeks of a high phosphorus regimen;
and c) to compare the effect of WR-272 I to that of prior
parathyroidectomy.
Figure 1 illustrates that before initiating the high phosphorus
diet (day 0), the plasma urea concentrations of the three NX
groups were elevated at similar levels above that of the SHAM
animals. After the onset of the high Pi diet, the marked rise in
plasma urea observed in untreated NX rats did not occur in
either NX-PTX nor in WR-272l-treated NX rats. WR-2721
treatment also completely prevented both the fall in plasma Ca
and the elevation in plasma Pi, and therefore the change in
plasma Ca x Pi product. In NX-PTX animals the high phos-
phorus regimen initially led to a decrement in plasma Ca and a
rise in plasma Pi. Then, both plasma Ca and plasma Pi remained
constant from the beginning of the second week to the end of
the experiment (Figs. 2 and 3). As indicated in the legend to
Table 3, the four experimental groups were eating virtually the
same amount of food during the four weeks of observation.
At the end of the experiment GFR was assessed by measuring
the clearance of 3H-inulin under steady i.v. infusion of the
glomerular filtration rate marker. In WR-272 1-treated or PTX-
NX rats GFR was half that of SHAM counterparts (P < 0.05).
However, it was twice as high as that of the untreated NX group
(P <0.001, Table 3).
The kidney Ca content (Fig. 4) was dramatically increased in
untreated NX rats. It was normal and slightly elevated in the
PTX-NX and WR-272 I-treated groups, respectively. Note that
no correlation was found between the level of plasma Ca and
the degree of nephrocalcinosis.
In animals belonging to these four experimental groups, the
plasma level of iPTH was determined about four hours after the
last injection of WR-2721 (Fig. 5). As expected, the plasma
iPTH level was markedly elevated in NX untreated as com-
pared to SHAM untreated animals. In NX + WR-272l, it was
significantly reduced as compared to NX untreated. However,
it was still much higher than that determined in SHAM untreat-
ed. In NX + PTX, iPTH was significantly lower than in SHAM
untreated.
Third study
This experiment was designed in order to determine the
efficacy of WR-272 I when started two weeks after the onset of
the high phosphorus diet. As presented in Table 4, the rise in
plasma urea and Pi and the fall in plasma Ca were counteracted,
at least partially, by WR-2721. However reversal of the deteri-
oration process could not be achieved.
Discussion
The present study can be analyzed from both pathophysiolog-
ical and therapeutical points of view. Indeed, on one side our
L
q)
0
E
E
C.,
C.,
E0
a.
3-
2-
1-
0-
+4+
f.-.-... +++1 - -
6-
L
1
2-
0-
Time, days
Fig. 3. Effrct of chronic administration of WR-2721 as compared to
prior pararhvroidectomy on the evolution of plasma P1 in subtotally
nephrectomized rats. Symbols are in Figure 1.
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Fig. 2. Effect of chronic administration of WR—2721 as compared to
prior parathvroidecromy on the evolution of plasma calcium in sub—
totally nephrectom,'zed rats (NX) fed a high P1 diet since day 0.
Symbols are in Figure I.
I I I
0 7 14 21 28
0
Sham NX NX
a
+
WA-2721
NX
+
PTX
All values are mean SEM. N — number uf rats. WR 2721 was administered at the daily dose of 20 mg/kg body wt s.c. during 4 weeks before
the determinatiuns of GFR and biochemical variables. The mean food consumption (g/day) during the 4 week period preceding these
determinations was: SHAM untreated, 19.1 0; NX untreated, 17.7 0.7; NX + WR-2721: 18.4 0.6; NX + PTX: 18.6 0.2.
a P < 0.05; b P < 0.01; C p < 0.001, fur difference between NX untreated and NX + WR-2721 treated rats. d P < (1.05; for difference between
NX + WR-2721 treated and SHAM untreated rats. The differences in plasma Ca and Pi between NX + WR 2721 and NX + PTX were significant
atP <0.01.
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WR-2721 PTX
Kidney dry wt (g) 0.24 0.50 0.36 0.32
÷0.01 +0.03
Fig. 4. ffect of chronic administration of Wi? 2721 as compared to
parothyroidectomy on the renal calcium content of .cuhtotally nephrec-
tomiz.ed (NX) and sham-operated (SHAM) rats fed a high Pi diet during
4 wee/cc. Intact or remnant kidneys were harvested from the same
groups of rats presented in Figures I, 2 and 3. Values are mean + SCM.
The kidney dry weight (d.w.) is expressed in gram (g). < 0.01 for
difference between NX untreated and NX WR-2721 treated rats. The
differences between NX + WR-272l or NX + PTX and SHAM were
not statistically significant.
findings underline the importance of PiTH in the progression of
CRF in an animal model combining renal mass reduction and
high Pi diet. On the other side, they suggest that WR-2721 could
be the prototype of a new class of drugs with therapeutical
potential for the prevention or at least the attenuation of the
deleterious consequences of hyperparathyroidism in CRF.
Fig. 5. Effect uf chronic ac/ministration of WR-2721 on the plasma
level qfiPTH. Animals belong to the same groups of rats presented in
Figures ito 4. Values are mean 5FM. Difference: between SHAM and
NX untreated, P < 0.001; NX + WR-2721 and NX untreated, P <
0.001; NX WR-2721 and SHAM, P <0.005; NX + PTX and SHAM,
P < 0.025.
Our results support the hypothesis that in CRF, at least in
those forms with pronounced hyperparathyroidism, PiTH can
be implicated in the progressive reduction of the functional
capacity of the remaining ncphrons l2J. Indeed, in the model
used in the present study, parathyroidectomy as well as WR-
2721, an inhibitor of PTH secretion [14—I 8L prevented the fall in
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Table 3.
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Effect of chronic administration of WR-2721 as compared to prior parathyroidectomy on glomerular filtration rate (GFR) and plasma
biochemical variables in subtotally nephreetomized (NX) rats
Plasma urea Plasma Ca Plasma Pi
Inulin clearance Plasma Ca x Pi
N mi/mm mmol/litcr mmol2/liter
SHAM untreated 5 3.2 0.2 5.39 0.68 2.35 ÷ 0.05 1.91 0.16 4.49 + 0.43
NX untreated 6 1.0 ÷ 0.lC 25.00 2.55k t.94 0.l0a 4.70 + 073b 8.88 0.98k
NX WR-272l 5 .8 01d 11.89 2.l4 2.22 001d 1.72 0.12 3.82 0.27
NX + PTX 5 1.7 0.1 10.82 1.29 1.40 0.07 3.60 0.16 5.24 0.33
**
/
S
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Table 4. Effect of WR-272 I administered in subtotally nephrectomized (NX) rate two weeks after the onset of progressive renal failure
induced by high Pi diet
Days after Difference
high Pi diet 14 28 Day 28—Day 14 P
Plasma urea mmollliier
SHAM untreated 5.57 0.57 5.18 0.39 —0.39 0.46
NX untreated 13.86 18.18 0.61k' +4.32 1.43 <0.05
NX + WR-2721 12.07 096d 13.29 0.93 +1.22 0.79
Plasma Ca mmol/liier
SHAM untreated 2.46 0.03 2.26 0.01 —0.20 0.02
NX untreated 2.09 0.051 1.84 0.08a —0.26 0.04 <0.01
NX + WR-272l 2.17 0.06c 2.11 0.07 —0.06 0.09
Plasma Pi ,n,nolllcr
SHAM untreated 1.77 0.03 1.81 0.4 +0.03 0.04
NX untreated 3.24 022d 4.63 0.50 +1.39 0.33 <0.01
NX + WR-2721 2.83 0.22c 3.57 0.50 +0.74 0.31
All values are mean SEM. WR-2721 was administered at the daily dose of 20 mg/kg body wt s.c. for 2 weeks, from the end of the 2nd to the
end of the 4th week of the high Pi regimen. During the first two weeks, mean food consumption (g/day) was: SHAM untreated, 18.2 + 0; NX
untreated, 18.0 0.7: NX + WR-2721, 18.6 0.4. During the last two weeks, it was: SHAM untreated, 20 0; NX untreated, 18.0 0.7;
NX + WR-2721, 18.6 0.4.
a p < 0.05; h P < 0.01 for difference between NX untreated (N = 5) and NX + WR-2721 treated (N = 5) rats. C P < 0.01; d p < 0.001 for
difference between either NX untreated or NX + WR-272l treated and SHAM untreated (N = 4) rats.
The statistical significance of differences between values obtained at day 14 and 28 are indicated in the Table.
GFR and the consecutive rise in the plasma levels of both urea
and Pi. This protective effect was observed by starting the
WR-2721 treatment before and probably also after the deterio-
ration of renal function has started to take place. This protec-
tive effect could be explained by assuming that PTH favors
nephrocalcinosis by enhancing the intracellular deposition of
Ca in the renal parenchynia [8, 91. Analysis of the kidney Ca
content in the second experiment would support this interpre-
tation. Indeed, the renal Ca content was dramatically increased
in untreated NX rats, while it was normal or barely elevated in
PTX-NX or WR-272 1-treated NX rats..The amount of Ca found
in the renal tissue did not correlate at all with the mean plasma
Ca concentrations determined in the four experimental groups.
Thus, low plasma Ca level was associated with either very high
(untreated-NX) or normal (PTX-NX) kidney Ca content. There
was also a rather poor correlation between the Ca > P product
and the amount of Ca found in the renal tissue. A comparison of
the kidney Ca content (Fig. 4) and the level of plasma iPTH
(Fig. 5) strongly supports the notion that the PTH status is a
major determinant of the degree of Ca accumulation in the renal
parenchyma [9]. Hence, the preventive effect of WR-2721 on
the nephrocalcinotic process could be explained by the ability
of this drug to inhibit PTH secretion [14—18]. However, as
discussed below, this mechanism might only be part of the
whole story. Indeed, the dose and mode of administration used
in this study, did not suppress the secretion of PTH completely
(Fig. 5). Thus, for the same degree of renal insufficiency,
WR-272 I—treated NX animals differed from PTX-NX rats in
their plasma levels of PTH, Ca, and Pi.
In NX animals, WR-272l promoted as expected an initial
drop in plasma Ca two hours after its administration (data not
shown). However, the plasma Ca level and also that of Pi were
nearly normal twelve hours later, suggesting that PTH was
probably again secreted at a rate sufficient to preserve Ca and Pi
homeostasis. Such a preservation could be achieved because
WR-272l treatment protected the kidney from being progres-
sively damaged by the high Pi regimen. Thus, paradoxically, a
drug which acutely exerts an hypocalcemic effect [14—19] can,
when administered chronically at small doses in a model of CRF
with severe hyperparathyroidism, prevent the hypocalcemia
and hyperphosphatemia, these two alterations resulting from
kidney function deterioration.
Surprisingly, whereas WR-272l was able to completely pre-
vent the progression of renal insufficiency, it only partially
hindered the expression of severe hyperparathyroidism at the
bone level. A significant reduction in the indices of both bone
resorption and formation was achieved. However, they re-
mained clearly above the values recorded in animals with
normal renal functions. This quantitative difference between
the renal and skeletal responses could be explained by a
different sensitivity of these two target organs to PTH. Thus,
relatively moderate and transitory elevations of PTH release
might be sufficient for enhancing bone turnover, whereas only a
more severe and constant degree of hyperparathyroidism would
deteriorate kidney functions. Without discarding this hypothe-
sis, it is possible that WR-2721 may have an additional renal
protective action besides that of inhibiting PTH secretion.
The present study does not allow the exclusion of this
additional renal protective action that could be related to an
effect of WR-2721 on blood pressure. A 15 to 20% transient
reduction in systolic blood pressure has been recorded after
i.m. injection of 200 mg/kg of WR-2721 in anesthetized rats [26].
Such an amount is tenfold larger than the single dose adminis-
tered to the conscious rats used in the present study. Never-
theless, further investigations should definitely rule out that
WR-2721, given at the minimal dosage conferring full renal
protection in such a CRF model, does not significantly influence
the blood pressure level.
The additional renal protective action of WR-2721 could be
the result of an effect on the availability of dietary factors
known to influence the progression of CRF [22, 27, 28]. In our
experiments all animals were pairfed. A possible, but still
undescribed inhibitory influence of WR-2721 on the intestinal
absorption of proteins, Pi, cannot be excluded from our studies.
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Nevertheless, determination of the urinary excretion of urea
and P1 (data not shown) did not favor this possibility. A more
attractive hypothesis takes into account a well established
pharmacological property of WR-2721 [29, 30]. Indeed, this
compound with its sulfhydryl group can act as a free radical
scavenger [29—31]. Therefore, it is possible that this effect
which has been exploited in radio- and chemotherapy [29, 30],
may protect the kidney against the deleterious effect of PTH-
induced Ca accumulation. Pertaining to this assumption is the
evidence indicating that disturbances in both intracellular Ca
metabolism and free radical generation could be involved in the
tissue damage following acute ischemia of the kidney [32—34]. A
very recent report, showing a protective effect of the calcium
antagonist verapamil in CRF [351, suggests that these cellular
disturbances could also contribute to the progressive deteriora-
tion of renal function. WR-272l, like verapamil, might be a
valuable tool for further elucidating some pathophysiological
aspects of CRF at the cellular level.
In conclusion, this study indicates that in a CRF model with
severe secondary hyperparathyroidism, chronic administration
of WR-272l can prevent both nephrocalcinosis and progressive
deterioration of renal functions, and also reduce excessive bone
resorption. It suggests that WR-2721 might be a useful com-
pound in CRF, not only because it can act as an inhibitor of
PTH secretion, but also because it could protect against the
deleterious effect of secondary hyperparathyroidism on kidney
functions.
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